: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ovarian Neoplasms

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 457 articles:
HTML format

Single Articles

August 2026

CHAPMAN GC, Fedorenko O, Sheyn D, Reid A, et al
Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model.
Gynecol Oncol. 2026;212:199-206.
PubMed Abstract available

WESTIN SN, Belotte J, Felicetti B, Aghera V, et al
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.
Gynecol Oncol. 2026;212:173-180.
PubMed Abstract available

AINIO C, Caruso G, Alessi S, Aiello AA, et al
Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?
Gynecol Oncol. 2026;212:145-151.
PubMed Abstract available

HELPMAN L, Josephy D, Toderis L, Tkach V, et al
Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer- A quality improvement project.
Gynecol Oncol. 2026;212:57-63.
PubMed Abstract available

CHESS I, Holtzman S, Cox M, Leschly J, et al
"I was in the driver's seat": A qualitative analysis of factors promoting and delaying previvors' oophorectomy after risk-reducing salpingectomy.
Gynecol Oncol. 2026;211:200-207.
PubMed Abstract available

MARADIYA R, Kinloch M, De Leo A, de Biase D, et al
The real-world utility of homologous repair deficiency testing in BRCA1/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker.
Gynecol Oncol. 2026;211:148-152.
PubMed Abstract available

MAIORANO MFP, Cormio G, De Serio I, Torzillo FP, et al
Occult invasive and preneoplastic lesions at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A multicenter retrospective cohort study.
Gynecol Oncol. 2026;211:29-36.
PubMed Abstract available

July 2026

LEITE LF, da Conceicao LD, de Almeida LFC, de Albuquerque LZ, et al
Ovarian cancer global trends and disparities across 204 countries and territories.
Gynecol Oncol. 2026;211:208-216.
PubMed Abstract available

SEGUIN CL, Eckel A, Howard DH, Peters MLB, et al
Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.
Gynecol Oncol. 2026;211:178-184.
PubMed Abstract available

ZHAO CL, Wang XP, Wei K, Ge YJ, et al
Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian Cancer: Expression and clinicopathological correlations.
Gynecol Oncol. 2026;211:162-170.
PubMed Abstract available

BARBER EL, Wei JJ, Strickland AL, Moroney JW, et al
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
Gynecol Oncol. 2026;211:171-177.
PubMed Abstract available

ZIMMERMAN J, Dadgar N, Krivak TC, Crafton SM, et al
Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.
Gynecol Oncol. 2026;211:138-141.
PubMed

HAIGHT PJ, Sakach JC, Chambers LM, Backes FJ, et al
Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?
Gynecol Oncol. 2026;211:132-137.
PubMed Abstract available

RICH BS, Fishbein JS, Purcell LN, Murphy JT, et al
Immature teratoma of the ovary with microscopic yolk sac tumor in children and adolescents: A multi-institutional study.
Gynecol Oncol. 2026;211:125-131.
PubMed Abstract available

RICH BS, Fishbein JS, Purcell LN, Murphy JT, et al
Immature teratoma of the ovary in children and adolescents: A multi-institutional study of characteristics and management.
Gynecol Oncol. 2026;211:115-124.
PubMed Abstract available

CATENA U, Dinoi G, Masciullo V, D'Alessandris N, et al
Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach.
Gynecol Oncol. 2026;211:108-114.
PubMed Abstract available

ROLLER L, Zhou N, Atre I, Xiong N, et al
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.
Gynecol Oncol. 2026;211:98-107.
PubMed Abstract available

SHAHIN MS, Lorusso D, Backes FJ, Barretina-Ginesta MP, et al
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2026;211:79-88.
PubMed Abstract available

HAZNEDAR T, Durante S, Lazzari R, Corrao G, et al
Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours.
Gynecol Oncol. 2026;210:140-147.
PubMed Abstract available

LANGSTRAAT CL, Ostby SA, Vu A, Kalogera ES, et al
Innovation through standardization: Reducing the ileostomy rates while targeting zero anastomotic leaks at cytoreductive surgery.
Gynecol Oncol. 2026;210:49-54.
PubMed Abstract available

LLOYD-ELLIS S, Kaur P, Kwon JS, Dawson L, et al
Uptake of risk-reducing medical interventions among female BRCA1/2 pathogenic variant carriers: A population-based study in British Columbia.
Gynecol Oncol. 2026;210:41-48.
PubMed Abstract available

June 2026

CHAMBERS LM, Spakowicz D, Chalif J, O'Connor R, et al
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.
Gynecol Oncol. 2026;211:74-78.
PubMed Abstract available

KOURI A, Menzies A, Stearns K, McGough C, et al
A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.
Gynecol Oncol. 2026;211:67-73.
PubMed Abstract available

MONTASSIER T, Laas E, Hotton J, Berton-Rigaud D, et al
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.
Gynecol Oncol. 2026;211:59-66.
PubMed Abstract available

YARUNIN A, Qiu P, Li X, Lukashchuk N, et al
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer.
Gynecol Oncol. 2026;210:217-225.
PubMed Abstract available

SULEIMAN R, Mokshagundam S, Block MS, Wahner Hendrickson AE, et al
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.
Gynecol Oncol. 2026;211:9-16.
PubMed Abstract available

BERGERON AM, Kisiel M, Lavecchia M, Mah S, et al
Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?
Gynecol Oncol. 2026;211:23-28.
PubMed Abstract available

LEE J, Seo K, Kim J, Son JH, et al
Corrigendum to "Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer" [Volume 208, May 2026, Pages 85-90].
Gynecol Oncol. 2026;211:8.
PubMed

ALASHQAR A, Clark M, Gross CP, Spatz ES, et al
Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study.
Gynecol Oncol. 2026;211:17-22.
PubMed Abstract available

MAH SJ, Bergeron AM, Hanley G, Yang I, et al
Opportunistic salpingectomy during non-gynecologic surgery: Canadian surgeons' experience, barriers and facilitators.
Gynecol Oncol. 2026;211:1-7.
PubMed Abstract available

GAILLARD S, Parker J, Broadwater G, Duska L, et al
Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.
Gynecol Oncol. 2026;210:208-216.
PubMed Abstract available

TANG X, Huang H, Peipert JD, Zola A, et al
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.
Gynecol Oncol. 2026;210:174-182.
PubMed Abstract available

KONG TW, Lee J, Kim J, Son JH, et al
A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors: (LARGES): Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3005).
Gynecol Oncol. 2026;210:148-152.
PubMed Abstract available

LEE YJ, Park J, Kim YN, Kim S, et al
Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure.
Gynecol Oncol. 2026;210:131-139.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Ceccaroni M, et al
Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].
Gynecol Oncol. 2026;210:113.
PubMed

KARLSEN NS, Hogdall CK, Dreisler E, Sakse AE, et al
Adding HE4 to the IOTA ADNEX model for differentiating adnexal masses: A Danish prospective, multicenter study.
Gynecol Oncol. 2026;209:111-119.
PubMed Abstract available

ZHANG X, Shahryari J, Kingsley LG, McCluggage WG, et al
Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract.
Gynecol Oncol. 2026;209:62-68.
PubMed Abstract available

PANDRAKLAKIS A, Shearer AM, Ellis LB, Oikonomou MD, et al
Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.
Gynecol Oncol. 2026;210:95-105.
PubMed Abstract available

May 2026

SMICK AH, Zurek N, Taylor-Harding B, Karlan BY, et al
Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.
Gynecol Oncol. 2026;210:55-62.
PubMed Abstract available

BORCINOVA M, Knize M, Brtnicky T, Presl J, et al
Multimodal prehabilitation in patients with advanced ovarian cancer.
Gynecol Oncol. 2026;210:10-19.
PubMed Abstract available

FINCH L, Dagher C, Harlev C, Finlan M, et al
Preoperative hypoalbuminemia and survival among patients selected for primary cytoreduction in advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2026;209:138-145.
PubMed Abstract available

JAMIESON A, Kwon J, Gao T, Lee J, et al
Assessing the essential parameters of race, ethnicity and geography in endometrial cancer and the impact on presentation, treatment and outcomes.
Gynecol Oncol. 2026;209:158-166.
PubMed Abstract available

PHUNG MT, Barroilhet LM, Binkley N, Gangnon RE, et al
Longitudinal dynamics of post-diagnosis frailty among older women with ovarian cancer.
Gynecol Oncol. 2026;209:99-106.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Ceccaroni M, et al
Endometriosis and ovarian cancer risk.
Gynecol Oncol. 2026;209:88-98.
PubMed Abstract available

SHACHAR E, Rotkop G, Haas R, Frankenthal R, et al
Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.
Gynecol Oncol. 2026;209:77-87.
PubMed Abstract available

GUIJARRO-CAMPILLO AR, Gonzalez-Gil A, Gil-Gomez E, Olivares-Ripoll V, et al
Corrigendum to "Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery" [Gynecol Oncol. 2026 Apr;207:16
Gynecol Oncol. 2026;209:75-76.
PubMed

LUKEY A, Salmanpour A, Kaur P, Berchuck A, et al
Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis.
Gynecol Oncol. 2026;209:69-74.
PubMed Abstract available

GRUBE M, Ribeiro de Souza B, Neilson A, Tinker A, et al
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.
Gynecol Oncol. 2026;209:48-55.
PubMed Abstract available

LUDMIR D, Huang Y, Xu X, Dioun S, et al
Impact of lymphadenectomy on survival outcomes for stage I malignant ovarian germ cell tumors.
Gynecol Oncol. 2026;209:40-47.
PubMed Abstract available

MUSA FB, Boyle TAC, Lim JT, Moore J, et al
Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.
Gynecol Oncol. 2026;209:33-39.
PubMed Abstract available

SAULE C, Laas E, Weber N, Bataillon G, et al
Peritoneal cancer risk after risk reducing salpingo-oophorectomy, impact of mutational status and STIC lesions.
Gynecol Oncol. 2026;208:1-7.
PubMed Abstract available

April 2026

SORRENTINO L, Bogani G, Chiappa V, Lalli L, et al
Predictive features of anastomotic leakage after colorectal resection in complex multivisceral cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2026;209:1-6.
PubMed Abstract available

CAGDAS EK
Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses.
Gynecol Oncol. 2026;209:7-14.
PubMed Abstract available

LIU JB, He TX, Zeng C, Kaur MN, et al
Association of surgical complexity with patient-reported outcomes among patients with ovarian cancer.
Gynecol Oncol. 2026;208:106-112.
PubMed Abstract available

LEE J, Seo K, Kim J, Son JH, et al
Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Gynecol Oncol. 2026;208:85-90.
PubMed Abstract available

AGUSTI N, Rauh-Hain JA
Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection.
Gynecol Oncol. 2026;207:A1-A2.
PubMed

SAWAYA K, Maraghe M, Metzger S, Heming CM, et al
Identifying ovarian cancer with AI analysis of abdominal CT scans.
Gynecol Oncol. 2026;207S:30-37.
PubMed Abstract available

PARANJPE R, Chen C, Sun Y, Hong JL, et al
Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.
Gynecol Oncol. 2026;208:69-76.
PubMed Abstract available

March 2026

SCHREUDER GOEDHEIJT M, Aronson SL, Sonke GS, van Driel WJ, et al
Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial.
Gynecol Oncol. 2026;208:54-62.
PubMed Abstract available

KAILASAM A, De Vitis L, Murphy B, Cucinella G, et al
The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer.
Gynecol Oncol. 2026;208:48-53.
PubMed Abstract available

BORKAR SR, Tasman JG, Bakkum-Gamez JN, Cheney MC, et al
Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.
Gynecol Oncol. 2026;208:41-47.
PubMed Abstract available

ALTAYF A, Nelson G, Chiva LM, Restaino S, et al
The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials.
Gynecol Oncol. 2026;208:22-31.
PubMed Abstract available

LEE MW, Friedman EL, Erfani H, Keymeulen S, et al
Assessment of survival and clinicopathologic characteristics associated with lymph node isolated tumor cells in epithelial ovarian cancer.
Gynecol Oncol. 2026;207:50-56.
PubMed Abstract available

NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
Corrigendum to 'Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer' [Gynecologic Oncology 204 (2026) 184-193].
Gynecol Oncol. 2026;207:48-49.
PubMed

DWYER E, Kennedy L, Bethune D, Katz R, et al
Granulosa cell tumors: Initial surgical approach and recurrence.
Gynecol Oncol. 2026;206:9-14.
PubMed Abstract available

February 2026

GUIJARRO-CAMPILLO AR, Gonzalez-Gil A, Gil-Gomez E, Olivares-Ripoll V, et al
Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery.
Gynecol Oncol. 2026;207:16-22.
PubMed Abstract available

INAN M, Akar Inan S, Aypak C, Turkmen O, et al
Emily vs. Lakisha: Quantifying socioeconomic and structural disparities in AI-generated ovarian cancer care plans.
Gynecol Oncol. 2026;207:7-15.
PubMed Abstract available

TEWARI S, Youssef A, Li S, Stewart T, et al
Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer.
Gynecol Oncol. 2026;207:1-6.
PubMed Abstract available

BESHAR I, Khorshid A, Somasegar S, Kennedy L, et al
Pre-operative cross-sectional imaging of chest, abdomen, pelvis is not cost-effective for low-grade endometrial cancer.
Gynecol Oncol. 2026;206:93-98.
PubMed Abstract available

DUE LP, Ketabi Z, Hogdall C, Rasmussen ELK, et al
Clinico-pathological characteristics of adult granulosa cell tumors of the ovary and the role of staging surgery: A national database study.
Gynecol Oncol. 2026;206:74-81.
PubMed Abstract available

PALMIERI L, Bellone S, Demirkiran C, Hartwich TMP, et al
Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.
Gynecol Oncol. 2026;206:65-73.
PubMed Abstract available

GARKHAIL P, de Bruin PC, Boere IA, van der Aa MA, et al
Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study.
Gynecol Oncol. 2026;206:45-53.
PubMed Abstract available

HODENT S, Bakrin N, Rousset P, Kepenekian V, et al
Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort study.
Gynecol Oncol. 2026;206:32-38.
PubMed Abstract available

January 2026

PEREZ L, Kulkarni A, Lopez S, Brewer JT, et al
Understanding patient priorities: Sexual health and hereditary ovarian cancer syndromes.
Gynecol Oncol. 2026;205:113-119.
PubMed Abstract available

MATTHEWS BJ, Paskett ED, McLaughlin E, Von Ah D, et al
Risk of memory impairment in gynecologic cancer survivors in the Women's Health Initiative: Untangling effects of age, comorbidities, and cancer.
Gynecol Oncol. 2026;206:1-8.
PubMed Abstract available

BRODSKY AL, Tahan E, Celestino J, Tang X, et al
Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors.
Gynecol Oncol. 2026;205:99-104.
PubMed Abstract available

MORGAN JE, Chen L, Xu X, Dioun S, et al
Trends, predictors, and safety of ovarian preservation in premenopausal women with high-grade endometrioid and non-endometrioid endometrial cancers.
Gynecol Oncol. 2026;205:46-52.
PubMed Abstract available

SMITH HJ, Dinkins K, Liang MI, Chu DI, et al
Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy.
Gynecol Oncol. 2026;205:27-31.
PubMed Abstract available

ANNUNZIATA CM
Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.
Gynecol Oncol. 2026;204:A1-A2.
PubMed

DING M, Li X, Wang H, Jia X, et al
G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
Gynecol Oncol. 2026;204:9-16.
PubMed Abstract available

December 2025

LUDMIR D, Huang Y, Xu X, Dioun S, et al
Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors.
Gynecol Oncol. 2025;205:9-16.
PubMed Abstract available

LESNOCK J, Gaillard S, Tew WP
ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
Gynecol Oncol. 2025;204:251-253.
PubMed

WASHINGTON C, Pothuri B, Cadoo K, Drew Y, et al
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
Gynecol Oncol. 2025;204:218-227.
PubMed Abstract available

SHAHIN MS, Mathur R, Parthan A, Yerram P, et al
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Gynecol Oncol. 2025;204:202-209.
PubMed Abstract available

PEPLINSKI RM, Riordan JD, Schillo JL, Hannan EC, et al
Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines.
Gynecol Oncol. 2025;204:194-201.
PubMed Abstract available

NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer.
Gynecol Oncol. 2025;204:184-193.
PubMed Abstract available

EVANS HE, Firriolo AM, Houweling R, Kelada L, et al
Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study.
Gynecol Oncol. 2025;204:150-157.
PubMed Abstract available

WANG Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, et al
First experience with intraperitoneal (224)Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Gynecol Oncol. 2025;204:158-164.
PubMed Abstract available

HANSEN J, Suratkal J, Shah SN, Kelley J, et al
Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy.
Gynecol Oncol. 2025;204:143-149.
PubMed Abstract available

KRAICZY J, Yu B
Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC).
Gynecol Oncol. 2025;203:198-208.
PubMed Abstract available

FAN Y, Wang Q, Deng H, Liu Y, et al
Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.
Gynecol Oncol. 2025;203:119-129.
PubMed Abstract available

November 2025

SOPPE SE, Kuo TM, Lyratzopoulos G, DeRouen MC, et al
Symptom-related care and diagnoses before ovarian cancer detection: Patterns and differences by cancer stage.
Gynecol Oncol. 2025;204:100-108.
PubMed Abstract available

EVERT JSH, de Jonge PKJD, Zusterzeel PLM, Hobo W, et al
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
Gynecol Oncol. 2025;204:91-99.
PubMed Abstract available

HAYAKAWA M, Nakajima H, Harano K, Watanabe S, et al
Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.
Gynecol Oncol. 2025;204:70-78.
PubMed Abstract available

TOBONI MD, Evans ET, Scalise CB, Hardesty M, et al
Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
Gynecol Oncol. 2025;204:37-43.
PubMed Abstract available

LEE AJ, Jang EB, Suh DH, Chang SJ, et al
Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Onc
Gynecol Oncol. 2025;203:191-197.
PubMed Abstract available

ARYASOMAYAJULA C, Johnson CR, Francoeur AA, Sia TY, et al
Pathogenic germline variants among patients with ovarian cancer by self-reported ancestry: A commercial laboratory collaborative research registry study.
Gynecol Oncol. 2025;204:1-8.
PubMed Abstract available

FURUYA RL, Grither W, Evans MG, Wu S, et al
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.
Gynecol Oncol. 2025;204:17-22.
PubMed Abstract available

CHUNG YE, Kim SI, Noh JJ, Lee JY, et al
Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study.
Gynecol Oncol. 2025;203:185-190.
PubMed Abstract available

THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 19
Gynecol Oncol. 2025;203:182-183.
PubMed

TISCHER KM, Islam NS, McGree ME, Tapia AL, et al
Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy.
Gynecol Oncol. 2025;203:165-170.
PubMed Abstract available

WASHINGTON C, Dwivedi SKD, Gunderson-Jackson C, Walker J, et al
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
Gynecol Oncol. 2025;203:158-164.
PubMed Abstract available

PARK J, Lee D, Kim S, Kim YN, et al
Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.
Gynecol Oncol. 2025;203:151-157.
PubMed Abstract available

October 2025

MOUFARRIJ S, Friedman CF, Freeman S, Green H, et al
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
Gynecol Oncol. 2025;203:97-104.
PubMed Abstract available

WHITE VM, Langdale LM, Eroh KD, Ackermann MK, et al
Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.
Gynecol Oncol. 2025;203:112-118.
PubMed Abstract available

LINDGREN A, Benseler A, Hogen L, May T, et al
Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.
Gynecol Oncol. 2025;203:90-96.
PubMed Abstract available

WANG Y, Li J, Yang Y, Lu X, et al
Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
Gynecol Oncol. 2025;203:67-74.
PubMed Abstract available

SKOLD C, Radestad AF, Bohlin KS, Bjurberg M, et al
Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study.
Gynecol Oncol. 2025;203:59-66.
PubMed Abstract available

ANDRES S, Tannous A, Kahn RM, Yeoshoua E, et al
Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter?
Gynecol Oncol. 2025;203:35-42.
PubMed Abstract available

MANNING B, Banerjee S, Hawkins TB, Winn-Deen ES, et al
Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.
Gynecol Oncol. 2025;203:26-34.
PubMed Abstract available

HOTTON J, Gaillard T, Paoletti X, Raimond E, et al
Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2025;203:16-25.
PubMed Abstract available

MACHIDA H, Kawana K, Okamoto A, Yamagami W, et al
Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 2025;203:8-15.
PubMed Abstract available

MAURER T, Belau MH, Zyriax BC, Welsch G, et al
Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center study.
Gynecol Oncol. 2025;202:167-173.
PubMed Abstract available

HOLTZMAN S, Myers E, Havrilesky LJ, Yamada D, et al
Gynecologic oncology fellowship trends: Supply outpacing demand, geographical maldistribution.
Gynecol Oncol. 2025;202:162-166.
PubMed Abstract available

DAGHER C, Selenica P, Bakhuis CFJ, Green H, et al
Prognostic value of positive peritoneal cytology in FIGO 2009 stage IA grade 1 endometrioid endometrial cancer.
Gynecol Oncol. 2025;202:154-161.
PubMed Abstract available

KIM U, Oh BC, Bae J, Kang S, et al
Survival outcomes and treatment patterns in malignant ovarian sex cord-stromal tumors: A population-based analysis.
Gynecol Oncol. 2025;202:146-153.
PubMed Abstract available

BORDEN BA, Rodriguez-Hernandez A, Trottier M, Horiguchi M, et al
SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
Gynecol Oncol. 2025;202:125-130.
PubMed Abstract available

BLANK SV, Frey MK
Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 3 carriers: Why is this a question?
Gynecol Oncol. 2025;201:A3-A4.
PubMed

NEPHEW KP, Drapkin R, Lang J, Zhuravlev Y, et al
The 15th Biennial Rivkin Center ovarian cancer research symposium.
Gynecol Oncol. 2025;201:A1-A2.
PubMed Abstract available

September 2025

SOMASEGAR S, Zhang J, Fotopoulou C, Fumagalli D, et al
The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.
Gynecol Oncol. 2025;202:59-65.
PubMed Abstract available

YOH K, Desai VB, Gross CP, Spatz ES, et al
Physician variation in adopting opportunistic salpingectomy at the time of postpartum and interval sterilization for ovarian cancer risk reduction.
Gynecol Oncol. 2025;202:1-13.
PubMed Abstract available

ACKROYD SA, Sudilovsky G, Che Y, Wesevich A, et al
Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center.
Gynecol Oncol. 2025;201:203-209.
PubMed Abstract available

REBOUILLAT C, Pomel C, Bourdel N, Mimoun C, et al
Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequence.
Gynecol Oncol. 2025;201:167-175.
PubMed Abstract available

CHIAPPINELLI KB, Christie EL, Padmanabhan A
Biology of ovarian cancer: Models, microenvironment, and therapeutics: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:160-163.
PubMed Abstract available

August 2025

BRODSKY AL, Welte T, Vuttaradhi VK, Yang X, et al
Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models.
Gynecol Oncol. 2025;201:152-159.
PubMed Abstract available

BRUCE KH, Xu C, Shah RP, McGree ME, et al
Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?
Gynecol Oncol. 2025;201:137-143.
PubMed Abstract available

SMITH AJ, Acharya R, Ang L, Moore T, et al
"What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer.
Gynecol Oncol. 2025;201:118-122.
PubMed Abstract available

SOONG TR, Islam BN, Hunt K, Nadeem A, et al
Research is care: How patients and researchers can work together to bring the bedside back to the bench - a patient advocacy panel discussion: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:114-117.
PubMed Abstract available

LANITI DD, Verma P
State-of-the art in emerging therapeutics for ovarian cancer therapy.
Gynecol Oncol. 2025;201:109-113.
PubMed Abstract available

ZHANG N, Porter RL
Emerging approaches to enhance immune responses in ovarian cancer: 15th biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:97-101.
PubMed Abstract available

SOZEN H, Minareci Y, Toyran A, Tutar E, et al
Evaluation of total retroperitoneal en-bloc resection of multivisceral-peritoneal packet (TROMP) in advanced ovarian cancer: A single-center cohort study.
Gynecol Oncol. 2025;201:102-108.
PubMed Abstract available

ROBIN TP, Hu J, Jones BL, Patton T, et al
Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
Gynecol Oncol. 2025;200:175-179.
PubMed Abstract available

GASPAR-MAIA A, Sasamoto N
Prevention, early detection & interception: 15th biennial ovarian cancer research symposium.
Gynecol Oncol. 2025;201:83-85.
PubMed Abstract available

SIA TY, Moufarrij S, Milani J, Kane S, et al
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
Gynecol Oncol. 2025;201:60-68.
PubMed Abstract available

BRUBAKER LW, Merritt MA
Ovarian cancer health disparities: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:56-59.
PubMed Abstract available

APOSTOL AI, Kotsopoulos J, Gronwald J, Kim RH, et al
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
Gynecol Oncol. 2025;201:44-52.
PubMed Abstract available

CHATOR C, Chevrier M, Frenel JS, Guyon F, et al
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.
Gynecol Oncol. 2025;201:17-25.
PubMed Abstract available

BOGANI G, Fagotti A, Chiantera V, De Iaco P, et al
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Gynecol Oncol. 2025;200:161-168.
PubMed Abstract available

CLARKE MA, Wentzensen N, Kobel M, Erickson BK, et al
Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019.
Gynecol Oncol. 2025;200:137-144.
PubMed Abstract available

July 2025

BRODSKY AL, Sun C, Cobb L, Westin SN, et al
Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A clinicopathologic study of 39 cases.
Gynecol Oncol. 2025;200:130-136.
PubMed Abstract available

WANG JY, Simons EJ, Dingel A, Pike MM, et al
Impact of chemotherapy provider specialty on outcomes in ovarian cancer.
Gynecol Oncol. 2025;200:122-129.
PubMed Abstract available

MATULONIS UA, Vergote I, Moore KN, Martin LP, et al
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2025;200:96-104.
PubMed Abstract available

MCGAURAN M, Hyde S, Perera S, Lloyd M, et al
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study.
Gynecol Oncol. 2025;200:72-79.
PubMed Abstract available

LAVEN P, Wenzel HHB, van der Aa MA, Lambrechts S, et al
Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study.
Gynecol Oncol. 2025;200:51-57.
PubMed Abstract available

STOVER EH, Lee EK, Shapiro GI, Brugge JS, et al
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
Gynecol Oncol. 2025;200:22-32.
PubMed Abstract available

KOIKE Y, Fujiwara A, Seki T, Kochi Y, et al
The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;200:14-21.
PubMed Abstract available

HUBINETTE M, Sundstrom-Poromaa I, Persson S, Elenis E, et al
Polycystic ovary syndrome and the risk of ovarian tumours.
Gynecol Oncol. 2025;200:1-7.
PubMed Abstract available

BEKTAS O, Bektas K
Prognostic value of systemic inflammatory markers in predicting neoadjuvant platinum response and platinum resistance in advanced epithelial ovarian cancer: A peritoneal cancer index-based analysis.
Gynecol Oncol. 2025;199:147-151.
PubMed Abstract available

AINIO C, Rosanu M, Ribero L, Caruso G, et al
Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer.
Gynecol Oncol. 2025;199:133-138.
PubMed Abstract available

SU H, Shang X, Liu H, Tian M, et al
Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105).
Gynecol Oncol. 2025;199:124-132.
PubMed Abstract available

SILBERMAN JN, Benjamin A, Solk P, Matei D, et al
Fit4Surgery: A pilot randomized controlled trial to assess the feasibility of prehabilitation prior to debulking surgery for ovarian cancer.
Gynecol Oncol. 2025;199:116-123.
PubMed Abstract available

HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
Gynecol Oncol. 2025;199:96-102.
PubMed Abstract available

June 2025

GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
Gynecol Oncol. 2025;199:64-71.
PubMed Abstract available

WANG M, Dong T, Lucero M, Pan W, et al
Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
Gynecol Oncol. 2025;199:57-63.
PubMed Abstract available

KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
Gynecol Oncol. 2025;199:40-46.
PubMed Abstract available

VARGIU V, Rosati A, Santullo F, Figa M, et al
REACT bowel REcovery after CyToreductive surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;199:32-39.
PubMed Abstract available

BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
Gynecol Oncol. 2025;199:10-16.
PubMed Abstract available

DAMIAN FB, De Melo AC, Dal Molin GZ, Nogueira-Rodrigues A, et al
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
Gynecol Oncol. 2025;198:161-167.
PubMed Abstract available

BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
Gynecol Oncol. 2025;198:130-136.
PubMed Abstract available

FU Z, Borho L, Taylor SE, Kelemen LE, et al
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
Gynecol Oncol. 2025;198:112-129.
PubMed Abstract available

May 2025

KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
Gynecol Oncol. 2025;198:90-95.
PubMed Abstract available

IIDA Y, Churchman M, Hollis RL, Taylor S, et al
Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.
Gynecol Oncol. 2025;198:66-74.
PubMed Abstract available

NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
Gynecol Oncol. 2025;198:42-48.
PubMed Abstract available

KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
Gynecol Oncol. 2025;197:121-128.
PubMed Abstract available

EVANS E, Dholakia J, Abraham J, Hinton A, et al
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
Gynecol Oncol. 2025;197:139-145.
PubMed Abstract available

KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
Gynecol Oncol. 2025;197:116-120.
PubMed Abstract available

SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
Gynecol Oncol. 2025;197:102-109.
PubMed Abstract available

THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
PubMed Abstract available

April 2025

LOUKOVAARA M, Pasanen A, Butzow R
Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2025;197:96-101.
PubMed Abstract available

POVEDA A, Lheureux S, Colombo N, Cibula D, et al
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
Gynecol Oncol. 2025;197:74-82.
PubMed Abstract available

YOU B, Anderson C, Cecere SC, Carrot A, et al
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
Gynecol Oncol. 2025;197:66-73.
PubMed Abstract available

XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
Gynecol Oncol. 2025;197:34-42.
PubMed Abstract available

WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;197:11-18.
PubMed Abstract available

ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
Gynecol Oncol. 2025;196:137-145.
PubMed Abstract available

RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
Hysterectomy or not for borderline ovarian tumor in menopause?
Gynecol Oncol. 2025;196:152-159.
PubMed Abstract available

METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
Gynecol Oncol. 2025;196:129-136.
PubMed Abstract available

HABLASE R, Steinke J, Aslam A, Jose R, et al
Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
Gynecol Oncol. 2025;196:121-128.
PubMed Abstract available

GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
Gynecol Oncol. 2025;196:113-120.
PubMed Abstract available

KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2025;196:107-112.
PubMed Abstract available

VARGIU V, Santullo F, Scambia G, Naldini A, et al
STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
Gynecol Oncol. 2025;196:92-98.
PubMed Abstract available

HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
MUTYH: Possibly another important gene in ovarian cancer?
Gynecol Oncol. 2025;196:59-61.
PubMed

BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
Signal transduction pathway activity in adult-type granulosa cell tumor samples.
Gynecol Oncol. 2025;195:6-11.
PubMed Abstract available

March 2025

MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Gynecol Oncol. 2025;195:192-199.
PubMed Abstract available

ETHIER JL, Shephard C, Granados DP, Dutta N, et al
Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
Gynecol Oncol. 2025;196:1-9.
PubMed Abstract available

JOHANNET P, Flint M, Chui MH, Konner J, et al
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
Gynecol Oncol. 2025;195:173-179.
PubMed Abstract available

LI Y, Wu M, Liu Q, Huang C, et al
Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
Gynecol Oncol. 2025;195:165-172.
PubMed Abstract available

SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
Gynecol Oncol. 2025;195:144-148.
PubMed Abstract available

CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
Gynecol Oncol. 2025;195:106-114.
PubMed Abstract available

SALINARO J, Singh K, Sands N, Gill V, et al
Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
Gynecol Oncol. 2025;195:115-121.
PubMed Abstract available

LI X, Wang Z, Man X, Dai X, et al
Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
Gynecol Oncol. 2025;195:34-44.
PubMed Abstract available

HICKS A, Borho L, Elishaev E, Berger J, et al
All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
Gynecol Oncol. 2025;195:26-33.
PubMed Abstract available

MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
Gynecol Oncol. 2025;195:16-25.
PubMed Abstract available

HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Gynecol Oncol. 2025;194:145-152.
PubMed Abstract available

LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
Gynecol Oncol. 2025;194:125-130.
PubMed Abstract available

ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
Gynecol Oncol. 2025;194:1-10.
PubMed Abstract available

February 2025

ASARE A, Previs RA, Spinosa D, Fellman B, et al
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Gynecol Oncol. 2025;194:112-118.
PubMed Abstract available

ALVERO AB, Wu S, Farrell A, Kim S, et al
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
Gynecol Oncol. 2025;194:71-79.
PubMed Abstract available

SUN H, Huo X, Bi X, Cao D, et al
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
Gynecol Oncol. 2025;194:60-70.
PubMed Abstract available

MATSUO K, Agarwal J, Chen L, Furey KB, et al
Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
Gynecol Oncol. 2025;194:51-59.
PubMed Abstract available

GAILLARD S, Verma N, Berg M, Harrison J, et al
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
Gynecol Oncol. 2025;194:41-47.
PubMed Abstract available

CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
Gynecol Oncol. 2025;194:33-40.
PubMed Abstract available

KIM J, Park SY, Kim JH, Lee SW, et al
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
Gynecol Oncol. 2025;194:25-32.
PubMed Abstract available

ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
Gynecol Oncol. 2025;194:18-24.
PubMed Abstract available

VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
Gynecol Oncol. 2025;194:11-17.
PubMed Abstract available

CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
Gynecol Oncol. 2025;193:148-155.
PubMed Abstract available

January 2025

MAKI PM, Rubin LH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2025;193:141-147.
PubMed Abstract available

TOBONI MD, Dinkins K, Wu S, Mattox T, et al
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Gynecol Oncol. 2025;193:89-97.
PubMed Abstract available

WANG H, Zhu J, Zou D, Rao Q, et al
Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol. 2025;193:58-64.
PubMed Abstract available

RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2025;193:49-57.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol. 2025;193:30-40.
PubMed Abstract available

MARINO G, Marchetta L, Negri S, Testa F, et al
Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
Gynecol Oncol. 2025;192:89-93.
PubMed Abstract available

December 2024

KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
Gynecol Oncol. 2024;192:155-162.
PubMed Abstract available

AZAIS H, Brochard C, Taly V, Benoit L, et al
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol. 2024;192:145-154.
PubMed Abstract available

MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Gynecol Oncol. 2024;192:128-136.
PubMed Abstract available

GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Gynecol Oncol. 2024;192:120-127.
PubMed Abstract available

PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
Gynecol Oncol. 2024;192:102-110.
PubMed Abstract available

November 2024

SHU T, Liang Y, Zhang S, Sun T, et al
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
Gynecol Oncol. 2024;192:94-101.
PubMed Abstract available

BORHO L, Elishaev E, Bao R, O'Brien E, et al
Association of neighborhood social vulnerability with ovarian cancer survival.
Gynecol Oncol. 2024;192:32-39.
PubMed Abstract available

SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
Gynecol Oncol. 2024;192:65-72.
PubMed Abstract available

FRANCIS KE, Simon S, Gebski V, Joly F, et al
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Gynecol Oncol. 2024;192:50-55.
PubMed Abstract available

MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
Gynecol Oncol. 2024;192:8-14.
PubMed Abstract available

HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
Gynecol Oncol. 2024;192:1-7.
PubMed Abstract available

LEE AW, Poynor V, Siddiqui S
Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
Gynecol Oncol. 2024;191:292-298.
PubMed Abstract available

WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
Gynecol Oncol. 2024;190:124-130.
PubMed Abstract available

METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
Gynecol Oncol. 2024;190:62-69.
PubMed Abstract available

TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
Gynecol Oncol. 2024;190:18-27.
PubMed Abstract available

October 2024

MOORE KN, Lorusso D, Oaknin A, Oza A, et al
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Gynecol Oncol. 2024;191:249-258.
PubMed Abstract available

GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
Gynecol Oncol. 2024;191:233-239.
PubMed Abstract available

HICKEY M, Trainer AH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
Gynecol Oncol. 2024;191:201-211.
PubMed Abstract available

YONEMORI K, Boni V, Min KG, Meniawy TM, et al
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Gynecol Oncol. 2024;191:172-181.
PubMed Abstract available

OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
Gynecol Oncol. 2024;191:124-131.
PubMed Abstract available

PINTO P, Moro F, Alcazar JL, Alessi S, et al
Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
Gynecol Oncol. 2024;191:132-142.
PubMed Abstract available

CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
Gynecol Oncol. 2024;191:86-94.
PubMed Abstract available

RUSHTON T, Krause HB, Samec T, Elliott A, et al
Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:80-85.
PubMed Abstract available

LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Gynecol Oncol. 2024;191:74-79.
PubMed Abstract available

September 2024

WAN S, Gao Y, Wu S, Wang H, et al
Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
Gynecol Oncol. 2024;191:56-66.
PubMed Abstract available

LI X, Argenta PA, Brown K, Honeyfield K, et al
Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
Gynecol Oncol. 2024;191:25-30.
PubMed Abstract available

JANG EB, Lee AJ, So KA, Lee SJ, et al
Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol. 2024;191:19-24.
PubMed Abstract available

NIEF CA, Long SE, McCleary TL, Kidd E, et al
Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
Gynecol Oncol. 2024;190:298-306.
PubMed Abstract available

BROWN J, Miller A, Holman LL, Backes F, et al
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Gynecol Oncol. 2024;190:283-290.
PubMed Abstract available

ADJEI NN, Haas A, Zhao H, Primm KM, et al
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
Gynecol Oncol. 2024;190:255-261.
PubMed Abstract available

MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2024;190:230-235.
PubMed Abstract available

August 2024

MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
Gynecol Oncol. 2024;190:146-152.
PubMed Abstract available

QI C, Lyu M, Yao Z, Zhang F, et al
SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
Gynecol Oncol. 2024;190:167-178.
PubMed Abstract available

SKOF E, Stegel V, Dragos VS, Blatnik A, et al
Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
Gynecol Oncol. 2024;190:104-112.
PubMed Abstract available

BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
Gynecol Oncol. 2024;190:119-123.
PubMed Abstract available

YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
Gynecol Oncol. 2024;190:113-118.
PubMed Abstract available

LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
Quality of life and survivorship in patients with low-grade ovarian cancer.
Gynecol Oncol. 2024;190:96-103.
PubMed Abstract available

ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
Gynecol Oncol. 2024;190:53-61.
PubMed Abstract available

YOKOI A, Machida H, Shimada M, Mastuo K, et al
Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;190:42-52.
PubMed Abstract available

CUN HT, Bernard L, Lande KT, Lawson BC, et al
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
Gynecol Oncol. 2024;189:138-145.
PubMed Abstract available

VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
Gynecol Oncol. 2024;189:111-118.
PubMed Abstract available

STROOT IAS, Bart J, Hollema H, Jalving M, et al
Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
Gynecol Oncol. 2024;187:198-203.
PubMed Abstract available

VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2024;187:113-119.
PubMed Abstract available

July 2024

JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
Gynecol Oncol. 2024;189:101-108.
PubMed Abstract available

GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
Gynecol Oncol. 2024;189:90-97.
PubMed Abstract available

FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;189:75-79.
PubMed Abstract available

KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol. 2024;189:68-74.
PubMed Abstract available

POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
Gynecol Oncol. 2024;189:37-40.
PubMed Abstract available

ANDRES S, Finch L, Iasonos A, Zhou Q, et al
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
Gynecol Oncol. 2024;189:30-36.
PubMed Abstract available

MAHONEY DE, Mukherjee R, Thompson J
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
Gynecol Oncol. 2024;189:24-29.
PubMed Abstract available

MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
Gynecol Oncol. 2024;189:16-23.
PubMed Abstract available

RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
Gynecol Oncol. 2024;186:110-116.
PubMed Abstract available

June 2024

FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
Gynecol Oncol. 2024;188:97-102.
PubMed Abstract available

MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
Gynecol Oncol. 2024;188:103-110.
PubMed Abstract available

MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
Gynecol Oncol. 2024;188:52-57.
PubMed Abstract available

KOH B, Ryu JY, Noh JJ, Hwang JR, et al
Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
Gynecol Oncol. 2024;188:60-70.
PubMed Abstract available

EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
Gynecol Oncol. 2024;188:58-59.
PubMed

BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
Gynecol Oncol. 2024;188:44-51.
PubMed Abstract available

BORHO L, Bao R, Elishaev E, Dinkins KD, et al
Association of allostatic load with overall survival in epithelial ovarian cancer.
Gynecol Oncol. 2024;186:204-210.
PubMed Abstract available

VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;187:128-138.
PubMed Abstract available

O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
Gynecol Oncol. 2024;186:199-203.
PubMed Abstract available

AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
Gynecol Oncol. 2024;187:241-248.
PubMed Abstract available

SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol. 2024;185:83-94.
PubMed Abstract available

May 2024

FRANCO S, Godley LA
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
Gynecol Oncol. 2024;187:235-240.
PubMed Abstract available

LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
Gynecol Oncol. 2024;187:227-234.
PubMed Abstract available

PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol. 2024;187:221-226.
PubMed Abstract available

YUAN G, Zhang K, Zheng H, Wu Y, et al
Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
Gynecol Oncol. 2024;187:212-220.
PubMed Abstract available

CARBALLO EV, Kim KH, Penn CA
Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
Gynecol Oncol. 2024;187:204-211.
PubMed Abstract available

LARAJA A, Connor Y, Poulson MR
The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
Gynecol Oncol. 2024;187:163-169.
PubMed Abstract available

MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Gynecol Oncol. 2024;187:170-177.
PubMed Abstract available

ZENATRI M, Perennec T, Michon C, Gernier F, et al
Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
Gynecol Oncol. 2024;187:139-144.
PubMed Abstract available

LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol. 2024;187:105-112.
PubMed Abstract available

ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
Gynecol Oncol. 2024;187:98-104.
PubMed Abstract available

FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;187:80-84.
PubMed Abstract available

PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
Gynecol Oncol. 2024;187:92-97.
PubMed Abstract available

LIANG S, Ge H, Zhou S, Tang J, et al
Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
Gynecol Oncol. 2024;187:64-73.
PubMed Abstract available

GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol. 2024;186:182-190.
PubMed Abstract available

PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
Gynecol Oncol. 2024;187:21-29.
PubMed Abstract available

MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
Gynecol Oncol. 2024;184:16-23.
PubMed Abstract available

April 2024

HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
Gynecol Oncol. 2024;186:176-181.
PubMed Abstract available

SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
Gynecol Oncol. 2024;186:170-175.
PubMed Abstract available

CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
Gynecol Oncol. 2024;186:161-169.
PubMed Abstract available

ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
Gynecol Oncol. 2024;186:144-153.
PubMed Abstract available

NELSON AT, Harris AK, Watson D, Kamihara J, et al
Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
Gynecol Oncol. 2024;186:117-125.
PubMed Abstract available

EHMANN S, Lam C, Zhou Q, Iasonos A, et al
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;186:104-109.
PubMed Abstract available

ESPINOSA I, D'Angelo E, Prat J
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Gynecol Oncol. 2024;186:94-103.
PubMed Abstract available

GITTO SB, Ihewulezi CJN, Powell DJ Jr
Adoptive T cell therapy for ovarian cancer.
Gynecol Oncol. 2024;186:77-84.
PubMed Abstract available

DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
Gynecol Oncol. 2024;186:69-76.
PubMed Abstract available

GIEN LT, Enserro DM, Block MS, Waggoner S, et al
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol. 2024;186:61-68.
PubMed Abstract available

SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
Gynecol Oncol. 2024;186:53-60.
PubMed Abstract available

KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Gynecol Oncol. 2024;183:103-114.
PubMed Abstract available

HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:42-52.
PubMed Abstract available

March 2024

MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:26-34.
PubMed Abstract available

HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
Gynecol Oncol. 2024;186:9-16.
PubMed Abstract available

PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Gynecol Oncol. 2024;183:61-67.
PubMed Abstract available

HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
Gynecol Oncol. 2024;183:39-46.
PubMed Abstract available

LEVINE BJ
Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
PubMed

CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
Gynecol Oncol. 2024;183:15-24.
PubMed Abstract available

BYRNE M, Sia TY, Fong C, Khurram A, et al
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
PubMed Abstract available

RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193.
PubMed Abstract available

NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
Real world challenges and disparities in the systemic treatment of ovarian cancer.
Gynecol Oncol. 2024;185:180-185.
PubMed Abstract available

CHEN W, Xie J, Gao C, Zhang C, et al
Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
Gynecol Oncol. 2024;182:108-114.
PubMed Abstract available

February 2024

COSTALES AB, Crane EK, Chambers L, Yao M, et al
Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
Gynecol Oncol. 2024;185:143-147.
PubMed Abstract available

SALMAN L, Covens A, Vicus D, Podolsky S, et al
The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
Gynecol Oncol. 2024;185:138-142.
PubMed Abstract available

RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol. 2024;185:128-137.
PubMed Abstract available

PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al
Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
Gynecol Oncol. 2024;185:116-120.
PubMed Abstract available

KRISTENSEN AK, Frandsen CLB, Nohr B, Viuff JH, et al
Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women.
Gynecol Oncol. 2024;185:108-115.
PubMed Abstract available

SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al
Determination of quality of life-related health utilities for surgical complications in ovarian cancer.
Gynecol Oncol. 2024;185:101-107.
PubMed Abstract available

DISIPIO T, Hartel G, Butow P, Webb PM, et al
Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers.
Gynecol Oncol. 2024;185:33-41.
PubMed Abstract available

ABADA E, Kim S, Jang H, Kheil M, et al
Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions.
Gynecol Oncol. 2024;185:25-32.
PubMed Abstract available

CHANG C, Cheng YY, Kamlapurkar S, White S, et al
GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.
Gynecol Oncol. 2024;185:8-16.
PubMed Abstract available

MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
PubMed Abstract available

WESSMAN S, Nister M, Kokaraki G, Pal N, et al
A comprehensive population-based study of malignant ovarian tumors, including histologic and immunohistochemical review, in children and adolescents 0-19 years old in Sweden between 1970 and 2014.
Gynecol Oncol. 2024;184:206-213.
PubMed Abstract available

SOMASEGAR S, Reddy RA, Chow S, Dorigo O, et al
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
Gynecol Oncol. 2024;184:190-197.
PubMed Abstract available

POTHURI B, Han S, Chase DM, Heitz F, et al
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;184:168-177.
PubMed Abstract available

SMITH AJB, Gleason EG, Andriani L, Heintz J, et al
Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?
Gynecol Oncol. 2024;184:160-167.
PubMed Abstract available

TELLES R, Zimmerman MB, Thaker PH, Slavich GM, et al
Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients.
Gynecol Oncol. 2024;184:139-145.
PubMed Abstract available

HARI A, Chang J, Villanueva C, Ziogas A, et al
Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
Gynecol Oncol. 2024;184:123-131.
PubMed Abstract available

YOON H, Suh DH, Kim K, No JH, et al
Evaluation of prognostic potential of beta-catenin and L1CAM expression according to endometrial cancer risk group.
Gynecol Oncol. 2024;184:132-138.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
Gynecol Oncol. 2024;181:186.
PubMed

VASTA FM, Cormio G, Cassani C, Bergamini A, et al
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
Gynecol Oncol. 2024;181:28-32.
PubMed Abstract available

January 2024

SANTORO A, Angelico G, Inzani F, Arciuolo D, et al
The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations.
Gynecol Oncol. 2024;184:57-66.
PubMed Abstract available

TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Gynecol Oncol. 2024;184:74-82.
PubMed Abstract available

WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2024;184:67-73.
PubMed Abstract available

MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Gynecol Oncol. 2024;184:51-56.
PubMed Abstract available

MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Gynecol Oncol. 2024;184:24-30.
PubMed Abstract available

WINKLER SS, Tian C, Casablanca Y, Bateman NW, et al
Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes.
Gynecol Oncol. 2024;184:31-42.
PubMed Abstract available

BAN D, Housley SN, Matyunina LV, McDonald LD, et al
A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024;182:168-175.
PubMed Abstract available

YANG Q, Peng X, Nian Z, Yuan S, et al
UCHL-3 as a potential biomarker of ovarian cancer.
Gynecol Oncol. 2024;182:156-167.
PubMed Abstract available

WEIGERT M, Cui XL, West-Szymanski D, Yu X, et al
5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
Gynecol Oncol. 2024;182:82-90.
PubMed Abstract available

TORTORELLA L, Cappuccio S, Giannarelli D, Nero C, et al
Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
Gynecol Oncol. 2024;182:57-62.
PubMed Abstract available

LEVINE MD, Wang H, Sriram B, Khan A, et al
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Gynecol Oncol. 2024;182:51-56.
PubMed Abstract available

KAHN RM, Ma X, Gordhandas S, Yeoshoua E, et al
Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
Gynecol Oncol. 2024;182:141-147.
PubMed Abstract available

CASANOVA J, Duarte GS, da Costa AG, Catarino A, et al
Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2024;182:99-107.
PubMed Abstract available

CRISTEA MC, Stewart D, Synold T, Ruel N, et al
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Gynecol Oncol. 2024;182:124-131.
PubMed Abstract available

FIFE AJ, Najor AJ, Aspir TB, Haines KE, et al
Reduced healthcare access contributes to delay of care in endometrial cancer.
Gynecol Oncol. 2024;182:115-120.
PubMed Abstract available

KIM SI, Joung JG, Kim YN, Park J, et al
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Gynecol Oncol. 2024;182:7-14.
PubMed Abstract available

HANNIBAL CG, Kjaer SK, Galanakis M, Hertzum-Larsen R, et al
History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study.
Gynecol Oncol. 2024;182:1-6.
PubMed Abstract available

GRESSEL GM, Frey MK, Norquist B, Senter L, et al
Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
Gynecol Oncol. 2024;181:170-178.
PubMed Abstract available

SZAMRETA EA, Monberg MJ, Desai KD, Li Y, et al
Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Gynecol Oncol. 2024;180:170-177.
PubMed Abstract available

ALSOMAIRI A, Himayda S, Altelmesani A, Lee YJ, et al
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
Gynecol Oncol. 2024;181:155-161.
PubMed Abstract available

December 2023

WU MF, Cheng XY, Wang DY, Lai YT, et al
Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
Gynecol Oncol. 2023;181:125-132.
PubMed Abstract available

PENVOSE KN, Reed SD, Sepulveda JMG, Mastylak A, et al
Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer.
Gynecol Oncol. 2023;181:91-98.
PubMed Abstract available

ALTMANN J, Schmitt W, Bashian N, Sehouli J, et al
A dramatic response to checkpoint inhibitor in a woman with small cell carcinoma of the hypercalcemic type of the ovary.
Gynecol Oncol. 2023;181:99-101.
PubMed Abstract available

CHAN JK, Tian C, Kesterson JP, Lin KY, et al
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
Gynecol Oncol. 2023;181:54-59.
PubMed Abstract available

KIM JH, Kim SI, Park EY, Kim ET, et al
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2023;181:33-39.
PubMed Abstract available

BENOIT L, Boudebza A, Bentivegna E, Nguyen-Xuan HT, et al
What is the most pertinent definition of malnutrition in epithelial ovarian cancer to assess morbidity and mortality?
Gynecol Oncol. 2023;181:12-19.
PubMed Abstract available

RICHARDSON MT, Barry D, Steinberg JR, Thirunavu V, et al
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
Gynecol Oncol. 2023;181:1-7.
PubMed Abstract available

CHAUHAN S, Langstraat CL, Fought AJ, McGree ME, et al
Relationship between frailty and nutrition: Refining predictors of mortality after primary cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2023;180:126-131.
PubMed Abstract available

YIN X, Zhao S, Zhang M, Xing J, et al
m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
Gynecol Oncol. 2023;180:99-110.
PubMed Abstract available

KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Gynecol Oncol. 2023;180:91-98.
PubMed Abstract available

CHASE DM, Annavarapu S, Tseng WY, Shi J, et al
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
Gynecol Oncol. 2023;180:79-85.
PubMed Abstract available

KAHN RM, Selenica P, Boerner T, Roche KL, et al
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Gynecol Oncol. 2023;180:35-43.
PubMed Abstract available

November 2023

NASIOUDIS D, Gysler S, Latif N, Cory L, et al
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Gynecol Oncol. 2023;180:1-5.
PubMed Abstract available

PRAISS AM, Hirani R, Zhou Q, Iasonos A, et al
Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2023;179:169-179.
PubMed Abstract available

AGUSTI N, Vidal-Sicart S, Paredes P, Celada-Castro C, et al
Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement.
Gynecol Oncol. 2023;179:145-151.
PubMed Abstract available

DILLEY J, Gentry-Maharaj A, Ryan A, Burnell M, et al
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Gynecol Oncol. 2023;179:123-130.
PubMed Abstract available

LIM YH, Dagher C, Abu-Rustum NR, Mueller JJ, et al
Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus.
Gynecol Oncol. 2023;179:152-157.
PubMed Abstract available

BAUMANN KE, Siamakpour-Reihani S, Dottino J, Dai Y, et al
High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
Gynecol Oncol. 2023;179:97-105.
PubMed Abstract available

BESHAR I, Moon AS, Darji H, Liu C, et al
Aberrant nuclear beta-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
Gynecol Oncol. 2023;179:85-90.
PubMed Abstract available

UCCELLA S, Bosco M, Mezzetto L, Garzon S, et al
Major vessel resection for complete cytoreduction in primary advanced and recurrent ovarian malignancies: A case series and systematic review of the literature - pushing the boundaries in oncovascular surgery.
Gynecol Oncol. 2023;179:42-51.
PubMed Abstract available

October 2023

KIM JH, Kim SI, Park EY, Ha HI, et al
Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
Gynecol Oncol. 2023;179:24-32.
PubMed Abstract available

RANDALL LM, O'Malley DM, Monk BJ, Coleman RL, et al
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol. 2023;178:161-169.
PubMed Abstract available

LI S, Zhang X, Zhang T, Zhang R, et al
Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors.
Gynecol Oncol. 2023;178:145-152.
PubMed Abstract available

BRZEZINSKA B, Mysona DP, Richardson KP, Rungruang B, et al
High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Gynecol Oncol. 2023;179:1-8.
PubMed Abstract available

LEDERMANN JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol. 2023;178:119-129.
PubMed Abstract available

IMTERAT M, Gebers G, Heitz F, Schneider S, et al
Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
Gynecol Oncol. 2023;178:96-101.
PubMed Abstract available

MCLAUGHLIN HD, Greco P, Straubhar AM, Rolston A, et al
Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
Gynecol Oncol. 2023;178:89-95.
PubMed Abstract available

KOBEL M, Yang RZ, Kang EY, Al-Shamma Z, et al
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Gynecol Oncol. 2023;178:80-88.
PubMed Abstract available

NGUYEN NT, Raetz A, Montoya D, Schilling V, et al
Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Gynecol Oncol. 2023;178:69-79.
PubMed Abstract available

JORGENSEN K, Denham C, Kanbergs A, Wu CF, et al
All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
Gynecol Oncol. 2023;178:60-68.
PubMed Abstract available

HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
Gynecol Oncol. 2023;177:150-156.
PubMed Abstract available

LIM H, Ju Y, Kim SI, Park JH, et al
Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
Gynecol Oncol. 2023;177:117-124.
PubMed Abstract available

SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
Gynecol Oncol. 2023;177:109-116.
PubMed Abstract available

NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Gynecol Oncol. 2023;177:86-94.
PubMed Abstract available

September 2023

MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
Gynecol Oncol. 2023;177:173-179.
PubMed Abstract available

WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol. 2023;177:165-172.
PubMed Abstract available

DUUS AH, Zheng G, Baandrup L, Faber MT, et al
Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
Gynecol Oncol. 2023;177:125-131.
PubMed Abstract available

MOUFARRIJ S, Havrilesky L, Jewell EL
Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
Gynecol Oncol. 2023;176:A1-A2.
PubMed

MCGONIGAL S, Wu R, Grimley E, Turk EG, et al
A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
Gynecol Oncol. 2023;176:139-146.
PubMed Abstract available

LIU Y, Chen J, Lu Z, Chang X, et al
Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
Gynecol Oncol. 2023;176:106-114.
PubMed Abstract available

August 2023

NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;177:72-85.
PubMed Abstract available

AO W, Kim HI, Tommarello D, Conrads KA, et al
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Gynecol Oncol. 2023;177:60-71.
PubMed Abstract available

MARJON N, Guerra R, Freeman A, Mak J, et al
Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
Gynecol Oncol. 2023;177:53-59.
PubMed Abstract available

KIM JH, Park KN, Park EY, Jang MJ, et al
Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
Gynecol Oncol. 2023;177:32-37.
PubMed Abstract available

HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Gynecol Oncol. 2023;177:38-45.
PubMed Abstract available

PIGNATA S, Bookman M, Sehouli J, Miller A, et al
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol. 2023;177:20-31.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October 2009, Pages 112-120].
Gynecol Oncol. 2023;175:193.
PubMed

TAYLOR DD, Gercel-Taylor C
Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July 2008, Pages 13-21].
Gynecol Oncol. 2023;175:192.
PubMed

July 2023

SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Gynecol Oncol. 2023;176:115-121.
PubMed Abstract available

MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al
Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer.
Gynecol Oncol. 2023;176:98-105.
PubMed Abstract available

HORVAT N, Causa Andrieu P, Meier A, Ji X, et al
A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
Gynecol Oncol. 2023;176:90-97.
PubMed Abstract available

DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Gynecol Oncol. 2023;176:76-81.
PubMed Abstract available

SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2023;176:69-75.
PubMed Abstract available

SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Gynecol Oncol. 2023;176:36-42.
PubMed Abstract available

O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Gynecol Oncol. 2023;176:16-24.
PubMed Abstract available

June 2023

TAYLOR KN, Li A, Manuel M, Rimel BJ, et al
The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer.
Gynecol Oncol. 2023;175:156-162.
PubMed Abstract available

COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306.
PubMed Abstract available

MORTON M, Haight PJ, Khadraoui W, Backes F, et al
"More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
Gynecol Oncol. 2023;175:81-87.
PubMed Abstract available

SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Gynecol Oncol. 2023;175:60-65.
PubMed Abstract available

POTHURI B, Blank SV, Myers TK, Hines JF, et al
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Gynecol Oncol. 2023;174:278-287.
PubMed

SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al
Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
Gynecol Oncol. 2023;175:25-31.
PubMed Abstract available

BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299.
PubMed

May 2023

PEIPERT JD, Goble S, Isaacson J, Tang X, et al
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol. 2023;175:1-7.
PubMed Abstract available

EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Gynecol Oncol. 2023;174:239-246.
PubMed Abstract available

PRAISS AM, Miller A, Smith J, Lichtman SM, et al
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol. 2023;174:213-223.
PubMed Abstract available

EURICH K, De La Cruz P, Laguna A, Woodman M, et al
Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
Gynecol Oncol. 2023;174:200-207.
PubMed Abstract available

HANVIC B, Lecuru F, Vanacker H, Pautier P, et al
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salome study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol. 2023;174:190-199.
PubMed Abstract available

QIU Y, Zha J, Ma A, Zhou T, et al
Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2023;174:175-181.
PubMed Abstract available

FENG Z, Fu Y, Li R, Li H, et al
Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
Gynecol Oncol. 2023;174:142-147.
PubMed Abstract available

THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Gynecol Oncol. 2023;174:157-166.
PubMed Abstract available

WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Gynecol Oncol. 2023;174:121-128.
PubMed Abstract available

KIM SR, Madariaga A, Hogen L, Vicus D, et al
Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
Gynecol Oncol. 2023;174:129-132.
PubMed Abstract available

MOYETT JM, Howell EP, Broadwater G, Greene M, et al
Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
Gynecol Oncol. 2023;174:114-120.
PubMed Abstract available

NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
Gynecol Oncol. 2023;173:138-150.
PubMed Abstract available

ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
Gynecol Oncol. 2023;174:89-97.
PubMed Abstract available

SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol. 2023;174:34-41.
PubMed Abstract available

SIA TY, Tew WP, Purdy C, Chi DS, et al
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol. 2023;173:130-137.
PubMed Abstract available

SAMUEL D, Kwon D, Huang M, Zhao W, et al
Disparities in refusal of surgery for gynecologic cancer.
Gynecol Oncol. 2023;174:1-10.
PubMed Abstract available

BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
Gynecol Oncol. 2023;172:106-114.
PubMed Abstract available

April 2023

HANDLEY KF, Mehta S, Martin AL, Biswas S, et al
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
Gynecol Oncol. 2023;173:114-121.
PubMed Abstract available

PEREZ L, Webster E, Bull L, Brewer JT, et al
Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
Gynecol Oncol. 2023;173:106-113.
PubMed Abstract available

GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gynecol Oncol. 2023;173:98-105.
PubMed Abstract available

CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
Gynecol Oncol. 2023;173:31-40.
PubMed Abstract available

PIGNATA S, Oza A, Hall G, Pardo B, et al
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol. 2023;172:121-129.
PubMed Abstract available

SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
Gynecol Oncol. 2023;173:1-7.
PubMed Abstract available

HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al
Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2023;173:8-14.
PubMed Abstract available

March 2023

BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Gynecol Oncol. 2023;172:98-105.
PubMed Abstract available

AREND R, Dholakia J, Castro C, Matulonis U, et al
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol. 2023;172:82-91.
PubMed Abstract available

MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol. 2023;172:72-77.
PubMed Abstract available

OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
Gynecol Oncol. 2023;172:29-35.
PubMed Abstract available

OSANN K, Wenzel L, McKinney C, Wagner L, et al
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Gynecol Oncol. 2023;171:151-158.
PubMed Abstract available

BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2023;171:106-113.
PubMed Abstract available

FOTOPOULOU C
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
Gynecol Oncol. 2023;170:A1-A3.
PubMed

LEE SS, Karpel HC, Oh C, Smith J, et al
Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
Gynecol Oncol. 2023;170:234-240.
PubMed Abstract available

LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol. 2023;170:93-101.
PubMed Abstract available

February 2023

HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;171:83-94.
PubMed Abstract available

JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
PubMed Abstract available

January 2023

JAMIESON A, Singh N, Huvila J, Gilks CB, et al
The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
PubMed

HAN C, McNamara B, Bellone S, Harold J, et al
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol. 2023;170:172-178.
PubMed Abstract available

MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol. 2023;170:38-45.
PubMed Abstract available

September 2022

GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
PubMed Abstract available

RUSH SK, Lees BF, Huang DS, Peterson MF, et al
Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
PubMed Abstract available

VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
PubMed Abstract available

August 2022

BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
PubMed Abstract available

MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum